Scientific Consultants and Advisors

Theratechnologies works with world-renowned scientists to move its research pipeline forward.


Come work at Theratechologies

Theratechnologies is constantly looking for talented, energetic people that share our values.

Dr. Richard Béliveau - Consultant

Richard Béliveau, Ph.D. in Biochemistry, is Scientific Director of the Chair in Prevention and Treatment of Cancer of the Université du Québec à Montréal.


He was Professor of Surgery and Physiology at Université de Montréal and held the Chair of Neurosurgery of the CHUM. He is an associate researcher at the Cancer Prevention Center in the Department of Oncology at McGill University and member of the Experimental Cancer Therapy Group at the Jewish General Hospital of Montreal. He is full Professor of Biochemistry at Université du Québec à Montréal and member of the Coalition Priorité Cancer au Québec. He is the founder of Angiochem and Katana Biopharma, two biotech companies that develop new drugs targeting brain disorders and various types of cancer.


He has published more than 250 articles in world-class scientific and medical journals. He also authored several best-selling books that have been translated into 28 languages across 37 countries, including “Foods that Fight Cancer”, “Cooking with Foods that Fight Cancer”, “Eating Well, Living Well”, “Death: the Scientific Facts”, “Samurai”, and “Preventing Cancer”. He wrote more than 550 medical research columns in the Journal de Montréal. He was awarded the Public’s Choice Prize at the Salon du Livre de Montréal, he was named Person of the Year by L’Actualité magazine and Personality of Quebec province by Au Québec newspaper. He was also named Emeritus alumnus of the Collège de Trois-Rivières, Université du Québec and Université Laval. He is Professor Emeritus of Biochemistry.

Dr. Éric A. Cohen - Advisor

Éric Cohen, Ph.D. is head of the Laboratory of Human Retrovirology at the Montreal Clinical Research Institute (IRCM) and Professor of Virology at the Université de Montréal.  He is also Lead Investigator of the Canadian HIV Cure Enterprise, CanCURE, a multidisciplinary research consortium dedicated to the study of long-lived HIV reservoirs and the development of effective therapeutic strategies towards an HIV remission. He serves on the Steering Committee of the Canadian HIV Trials Network and Scientific Advisory Committee of the Quebec AIDS Network. Dr. Cohen is a member of the editorial board of Retrovirology and a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.


Dr. Cohen has been involved in HIV research for the last three decades. His current work focuses on defining HIV-host interactions regulating viral replication, transmission and persistence, and on developing new therapeutic strategies to target persistent HIV reservoirs.

Dr. Steven K. Grinspoon - Advisor

Dr. Grinspoon is a Professor of Medicine, Harvard Medical School, Chief of the MGH Metabolism Unit, Director of the Nutrition Obesity Research Center at Harvard and Endowed Chair in Neuroendocrinology and Metabolism. He has had a long-standing interest in the metabolic complications and regulation of ectopic adipose tissue in obesity and lipodystrophic conditions, with a specific focus on HIV lipodystrophy. He has served on the World Health Organization Technical Advisory Group on Nutrition in HIV Disease and Chaired the American Heart Association State of the Science Conference on Cardiovascular Disease in HIV-infected patients, as well as a recent NIH-sponsored conference on the mechanisms and complications of obesity in HIV-infected patients.  In his research, he has investigated the effects of reduced pulsatile growth hormone secretion on metabolic dysregulation in obesity and was the first to propose the use of a GHRH analogue to increase endogenous GH secretion in lipodystrophy and generalized obesity. This strategy has shown that augmentation of endogenous GH pulsatility selectively reduces visceral fat, improves carotid IMT, and reduces inflammatory indices. This work led to the FDA approval of Tesamorelin for excess visceral fat accumulation in HIV-infected patients. For his work Dr. Grinspoon was awarded the 2016 Aurbach Laureate award in translational research from the Endocrine Society. More recently he has shown beneficial effects of Tesamorelin on liver fat and fibrosis progression among HIV-infected patients with nonalcoholic fatty liver disease. He has been selected for membership to the American Society of Clinical Investigation and the Association of American Physicians.